CAMBRIDGE, Mass., Aug. 3 /PRNewswire-FirstCall/ -- Verenium Corporation , a leading developer of biofuels derived from low-cost, abundant biomass and a pioneer in the development of high-performance specialty enzymes, announced today that Carlos A. Riva, President and Chief Executive Officer of Verenium, will be presenting at the 27th Annual Canaccord Adams Global Growth Conference. The presentation is scheduled to begin at 9:00 a.m. ET on Thursday, August 9, 2007 at the InterContinental Hotel in Boston.
More information about this event, including a live webcast, may be accessed by visiting the "Investor's" section of Verenium's website at http://www.verenium.com/. The webcast replay will be available approximately one hour after the live webcast ends and will be accessible for one month following the conference.
About Verenium
Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and health and nutrition markets. The Company possesses integrated, end-to-end capabilities in pre-treatment, novel enzyme development, fermentation, engineering, and project development and is moving rapidly to commercialize its proprietary technology for the production of ethanol from a wide array of feedstocks, including sugarcane bagasse, dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars. For more information on Verenium, visit http://www.verenium.com/ .
Forward Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include statements related to the Company's operations, capabilities, commercialization activities, and target markets, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's new and uncertain technologies, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, technological, regulatory, competitive and other risks related to development, production, and commercialization of cellulosic ethanol and other biofuels and the commercial prospects of those industries, Verenium's dependence on existing collaborations, including with the University of Florida, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercialized products, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, changes in the U.S. or global energy markets and risks and other uncertainties more fully described in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2007. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update these forward looking statements.
Contact:
Wendy Kelley
Investor Relations
Verenium Corporation
(858) 526-5437
